Introduction
============

Long-term oral anticoagulation with vitamin K antagonists could display the risk of hemorrhagic or thromboembolic complications. The occurrence of these potentially life-threatening complications depends on the accuracy of oral anticoagulant treatment. A periodic laboratory testing of international normalized ratio (INR) and a subsequent dose adjustment are therefore mandatory.

Long-term oral anticoagulation is a public health concern as, for instance, \~1% of the French population requires vitamin K antagonists. Moreover, it was associated with the highest rate of hospitalization due to iatrogenic effects in France during 2007.[@b1-vhrm-12-387] Several studies proposed guidelines for administrating and monitoring oral anticoagulation with vitamin K antagonists in children,[@b2-vhrm-12-387] with many difficulties in their use in this population especially in infants under the age of 12 months. Different reasons could explain this problem: the lack of patients' education, the complex pharmacokinetics and drug interactions of vitamin K antagonists, the need for continuous monitoring and dose adjustments, and patients' compliance.[@b3-vhrm-12-387]

The use of home testing devices to measure INR has been suggested as a potential way to improve the comfort and compliance of the patients and their families, the frequency of monitoring and, finally, the management and safety of long-term oral anticoagulation. Indeed, current practice guidelines suggest the strategy of self-management for patients treated with vitamin K antagonists who are motivated and can demonstrate competency in self-management strategies, including the self-testing equipment (Class IIb).[@b4-vhrm-12-387]

In pediatric patients, increased doses to obtain and maintain the therapeutic target INR, more frequent adjustments and INR testing, multiple medication, inconstant nutritional intake, difficult venepunctures, and the need to go to the laboratory for testing (interruption of school and parents work attendance) highlight these difficulties.[@b5-vhrm-12-387] The purpose of this section of our paper is to review the most relevant published studies of self-testing and self-management of INR for adult patients and children on oral anticoagulation.

Methods
=======

We considered only randomized controlled trials comparing the effects and the clinical outcomes of self-testing or self-management of oral anticoagulation therapy with standard monitoring and care, including personal physicians and anticoagulation hospitals or clinics. We included studies focusing on adult patients and children on oral anticoagulation therapy irrespective of the indication for treatment.

Results
=======

In the adult population, we identified 20 published randomized controlled trials that met the inclusion criteria ([Table 1](#t1-vhrm-12-387){ref-type="table"}). Fourteen trials included patients on oral anticoagulant treatment for any indication.[@b6-vhrm-12-387]--[@b19-vhrm-12-387] Four trials considered only patients on lifelong oral anticoagulation after heart valve replacement with a mechanical prosthesis.[@b20-vhrm-12-387]--[@b23-vhrm-12-387] Two trials included only patients on long-term anticoagulation for atrial fibrillation.[@b24-vhrm-12-387],[@b25-vhrm-12-387] Twelve trials analyzed the strategy of self-management6,8,10,12--15,17--19,21,25 while seven trials the strategy of self-testing.[@b7-vhrm-12-387],[@b11-vhrm-12-387],[@b16-vhrm-12-387],[@b20-vhrm-12-387],[@b22-vhrm-12-387]--[@b24-vhrm-12-387] Gadisseur et al reported the results of both self-management and self-testing.[@b9-vhrm-12-387]

In the pediatric population, we identified only one randomized controlled trial that met the inclusion criteria.[@b26-vhrm-12-387] Jones et al in 2011 published a review of the literature concerning oral anticoagulation therapy in children, and they demonstrated that time in therapeutic range was from 39% to 81% but they did not describe randomized trials of either self-testing or self-management.[@b27-vhrm-12-387]

Clinical effectiveness
----------------------

The best way to evaluate the clinical efficacy and safety of self-testing and self-management is the control of the anticoagulant effect. The simplest indicators of the anticoagulant effect are the mean INR within the target range and the mean time spent within the target range. Owing to our review of the literature, nine trials reported mean INR within the target range.[@b6-vhrm-12-387],[@b8-vhrm-12-387]--[@b10-vhrm-12-387],[@b12-vhrm-12-387],[@b15-vhrm-12-387],[@b20-vhrm-12-387],[@b21-vhrm-12-387],[@b25-vhrm-12-387] Every single trial showed a better INR control in the self-testing or self-management group but this improvement was statistically significant only in five trials.[@b12-vhrm-12-387],[@b15-vhrm-12-387],[@b20-vhrm-12-387],[@b21-vhrm-12-387],[@b25-vhrm-12-387] Improvements ranged from 3% to 17% ([Table 2](#t2-vhrm-12-387){ref-type="table"}). Moreover, 14 trials analyzed the mean time spent within the INR target range ([Table 3](#t3-vhrm-12-387){ref-type="table"}).[@b7-vhrm-12-387],[@b9-vhrm-12-387]--[@b17-vhrm-12-387],[@b21-vhrm-12-387]--[@b24-vhrm-12-387] Among these trials, 12 documented an improvement in the self-testing or -monitoring group,[@b7-vhrm-12-387],[@b9-vhrm-12-387],[@b10-vhrm-12-387],[@b13-vhrm-12-387]--[@b17-vhrm-12-387],[@b21-vhrm-12-387]--[@b24-vhrm-12-387] but the statistical significance was reached only in five trials.[@b7-vhrm-12-387],[@b15-vhrm-12-387],[@b16-vhrm-12-387],[@b21-vhrm-12-387],[@b22-vhrm-12-387] Finally, two trials did not show a beneficial effect in the intervention group.[@b11-vhrm-12-387],[@b12-vhrm-12-387]

Even if self-testing or self-management of oral anticoagulation is more effective or, at least, as effective as conventional care management, some authors argued against the correlation between improvement of INR control and decrease in major complications and call into serious question the usefulness of evaluating the safety of oral anticoagulation by using the percentage of mean INR and/or time within target range.[@b12-vhrm-12-387]

The use of point-of-care devices for routine INR measurements has demonstrated safety, reliability, and effectiveness in infants and children requiring long-term oral anticoagulation therapy.[@b28-vhrm-12-387],[@b29-vhrm-12-387]

Baumann et al in the EMPoWarMENT study[@b26-vhrm-12-387] have studied 28 wafarinized children performing self-testing for \>3 months and randomized them to self-testing at home or self-management. The mean age was 10 years,[@b1-vhrm-12-387]--[@b19-vhrm-12-387] and 93% were followed during 12 months. Mean number INR test over the study was around 22 either for self-testing or self-management. Time in therapeutic range was 77% for self-testing and 83% for self-management. INRs \>5 were not related to warfarin dosing decision but to unexpected illness. Patients with self-management made dose decisions consistent with the guidelines in 90% of time.

Clinical benefits
-----------------

The ideal endpoint of oral anticoagulation therapy studies is the evaluation of major complications. However, the reduction of oral anticoagulation-related complications -- namely, bleeding and thromboembolic events -- as a consequence of a better control of the anticoagulant treatment (as discussed earlier) is still a matter of debate.

When we take into consideration previous reviews of the literature calculating the overall effect size, there is general agreement on the reduction of thromboembolic complications determined by self-testing or self-management. Overall, these strategies show a 50% reduction of thromboembolic complications as compared to the control group.[@b3-vhrm-12-387],[@b30-vhrm-12-387],[@b31-vhrm-12-387]

Conversely, the analysis of bleeding complications is more challenging. Heneghan et al found a significant one-third reduction of hemorrhagic complications in their review published in 2006,[@b3-vhrm-12-387] but other investigators did not.[@b30-vhrm-12-387],[@b31-vhrm-12-387] These different conclusions should probably be explained by a nonhomogeneous definition of major and minor hemorrhagic complications used in every report.

Finally, the same consideration could be done to the analysis of mortality. In fact, Heneghan et al found different results in their reviews published in 2006 and 2012.[@b3-vhrm-12-387],[@b30-vhrm-12-387] In the former, there was a significant reduction of overall mortality in the self-testing/self-management group,[@b3-vhrm-12-387] while in the latter the difference was not statistically significant.[@b30-vhrm-12-387] The relative weight of oral anticoagulation control, thromboembolic complications, and bleeding in determining overall mortality is difficult to estimate and other factors may participate in the outcome of patients' population.

Previous studies in children have shown a rate of bleeding ranging from 0.5% to 1.7% with oral anticoagulation therapy, with only one death reported related to the patient anticoagulation therapy;[@b32-vhrm-12-387] only two prospective studies have reported thromboembolic events with a rate under 2% and 10% per patient year.

In the EMPoWarMENT study, there were no hemorrhagic or thromboembolic events, and baseline time in therapeutic range for the self-monitoring group was less than the self-testing group due to poor adherence in four patients.[@b27-vhrm-12-387] As an answer, it has been now well demonstrated that the ability of parents to use point-of-care monitor and parental knowledge is the major criterion for clinical effectiveness and benefits.

Quality of life assessment
--------------------------

The success of an effective oral anticoagulation could be also evaluated with the treatment-related quality of life. Our review of the literature identified six trials that assessed quality of life outcomes.[@b6-vhrm-12-387],[@b8-vhrm-12-387],[@b16-vhrm-12-387],[@b17-vhrm-12-387],[@b18-vhrm-12-387],[@b24-vhrm-12-387]

Sawicki et al evaluated at baseline and 6-month follow-up the treatment-related quality of life using a structured questionnaire containing 40 items.[@b6-vhrm-12-387] The 40 items covered five topics: general treatment satisfaction, self-efficacy, strained social network, daily hassles, and distress. General treatment satisfaction and daily hassles scores improved in the self-management group and remained unchanged in the routine care group. The scores of self-efficacy and distress improved in both groups but improved significantly more in the self-management group. The intervention had no significant effect on the strained social network scores. Interestingly, the general treatment satisfaction scores displayed the most pronounced improvement. Other investigators used the same structured questionnaire in order to perform a self-perceived assessment of the quality of care.[@b8-vhrm-12-387],[@b17-vhrm-12-387] As previously outlined, there were significant differences in all five categories of the questionnaire in favor of the self-management group: scores for general treatment satisfaction and self-efficacy were higher in the self-management group whereas the score for daily anxieties, distress, and strain were significantly lower. Moreover, Matchar et al evaluated patients' satisfaction with anticoagulation, measured with the Duke Anticoagulation Satisfaction Scale, and quality of life, measured with the Health Utilities Index Mark.[@b3-vhrm-12-387],[@b16-vhrm-12-387]

At 2 years (the minimum duration of follow-up), patient satisfaction with anticoagulation as measured by the Duke Anticoagulation Satisfaction Scale was greater in the self-testing group than in the clinic-testing group and a cumulative gain in health utilities according to the Health Utilities Index Mark 3 was noted in the self-testing group as compared with the clinic-testing group. Finally, Siebenhofer et al focused attention on elderly patients and found a pronounced improvement in general treatment satisfaction after participation in the self-management program.[@b18-vhrm-12-387]

Conversely, Khan et al did not find any difference in quality of life measurements and health beliefs about warfarin between the control and self-monitoring groups using the 36-item United Kingdom Short Form Health Survey and European Quality of Life questionnaire.[@b24-vhrm-12-387]

Two main studies have described the quality of life in children on home INR self-testing or self-management.[@b33-vhrm-12-387],[@b34-vhrm-12-387] KIDCLOT-PAC-QL^©^ was the first preliminarily validated inventory to assess quality of life in anticoagulated children; it determined confounders to therapy and may facilitate partnership in care.[@b33-vhrm-12-387] In 2013, Newall et al tried to evaluate the impact of a home INR self-testing on the quality of life of children and their families. In all, 55 parents and 35 children participated; time in therapeutic range was 71%, and parents reported statistically significant improvement in quality of life for themselves, their family, and their child.[@b34-vhrm-12-387]

Cost-effectiveness evaluation
-----------------------------

Our review identified only one trial performing a costs evaluation.[@b16-vhrm-12-387] In this study, costs were higher in the self-testing group but not significantly different from those in the clinic-testing group (difference = \$1,249; *P*=0.32).

Only one study has been found in the pediatric population as well.[@b35-vhrm-12-387] The home monitoring saved a total of 1 hour and 19 minutes per INR test and has a cost saving to society of \$66.83 per INR test compared to traditional care incorporating health sector costs, travel expenses, and lost time.

Discussion
==========

The self-testing and self-management of INR during oral anticoagulation is safe and effective and provides an accurate control of the anticoagulant treatment. Portable devices offer patients a more frequent and regular control of INR, thus reducing the intensity and frequency of supratherapeutic and subtherapeutic values. In fact, it has been demonstrated that there is a linear relationship between the frequencies of INR testing and quality of oral anticoagulation.[@b36-vhrm-12-387]

Nevertheless, this accurate control of oral anticoagulation does not automatically translate into a substantial reduction of major complications. In the largest randomized clinical trial -- THINRS (The Home INR Study) -- weekly home INR testing did not reduce the aggregate outcome of stroke, major bleeding, or death as compared to monthly clinic INR testing.[@b16-vhrm-12-387]

In contrast, there is a general agreement in the amelioration of the quality of life provided by the self-testing or self-management of INR. In fact, from a theoretical standpoint, patients should perform their INR measurements in the same laboratory in order to reduce the inter-laboratory variability, which can span from 10% to 30%.[@b37-vhrm-12-387] This dependence from the same laboratory could represent a major limitation of patients' personal or professional daily activities. Self-testing or self-management of oral anticoagulation might effectively face this limitation and this is clearly witnessed by a global improvement of general treatment satisfaction as compared to standard care.[@b6-vhrm-12-387],[@b8-vhrm-12-387],[@b16-vhrm-12-387]--[@b18-vhrm-12-387],[@b24-vhrm-12-387]

A structured teaching program is however of outmost importance and plays a key role in self-strategies of oral anticoagulation. This is even more important in children, elderly, or low-level education or social status patients.

Limitations
===========

Our review displays of course several limitations. Firstly, although comprehensive, we could have potentially missed some published studies. Moreover, the analysis of published data was not performed in a statistical manner and without any stratification according to the indications, frequency of tests or the length of the anticoagulant treatment, and different models of standard routine care. Finally, we did not take into consideration the type of education and training and the reasons and rate of dropout of the self-testing/self-management group.

Conclusion
==========

The present review article reported that self-testing and self-management for INR control provided a better control of the anticoagulant effect and improved patients' and their family quality of life. These findings would be very useful in the actual clinical setting.

And the reviewers would expect that the system and procedure of self-testing and self-management for INR control would evolve to be more user-friendly, and hope that especially in child patients, the novel anticoagulant therapy would be innovated to a stage wherean INR control would not necessary.

They are valuable and effective strategies of INR control. Despite an unclear relationship between INR control and clinical effects, these self-strategies provide a better control of the anticoagulant effect, improve patients' and their family quality of life, and are an appealing solution in term of cost-effectiveness. For children, structured education and knowledge evaluation by trained health care professionals, children, and their caregivers appear to be able to adjust their dose treatment safely and accurately. Further data are however necessary in order to best define those patients who might better benefit from this multidisciplinary approach.
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###### 

Most relevant published randomized controlled trials reporting self-testing and self-management of oral anticoagulation

  Author (year)                                     Indication to OA        Control group patients, n   Intervention group patients, n   Type of intervention
  ------------------------------------------------- ----------------------- --------------------------- -------------------------------- ----------------------
  Sawicki (1999)[@b6-vhrm-12-387]                   Any                     82                          83                               SM
  Beyth et al (2000)[@b7-vhrm-12-387]               Any                     162                         163                              ST
  Cromheecke et al (2000)[@b8-vhrm-12-387]          Any                     49                          49                               SM
  Kortke et al (2001)[@b20-vhrm-12-387]             Mechanical prosthesis   295                         305                              ST
  Sidhu et al (2001)[@b21-vhrm-12-387]              Mechanical prosthesis   48                          34                               SM
  Gadisseur et al (2003)[@b9-vhrm-12-387]           Any                     221                         99                               SM
  Khan et al (2004)[@b24-vhrm-12-387]               AF                      39                          40                               ST
  Sunderji et al (2004)[@b10-vhrm-12-387]           Any                     70                          69                               SM
  Gardiner et al (2005)[@b11-vhrm-12-387]           Any                     24                          29                               ST
  Menéndez-Jándula et al (2005)[@b12-vhrm-12-387]   Any                     369                         368                              SM
  Voller et al (2005)[@b25-vhrm-12-387]             AF                      101                         101                              SM
  Fitzmaurice et al (2005)[@b13-vhrm-12-387]        Any                     280                         337                              SM
  Christensen et al (2006)[@b14-vhrm-12-387]        Any                     50                          50                               SM
  Siebenhofer et al (2007)[@b15-vhrm-12-387]        Any                     96                          99                               SM
  Matchar et al (2010)[@b16-vhrm-12-387]            Any                     1457                        1465                             ST
  Azarnoush et al (2011)[@b22-vhrm-12-387]          Mechanical prosthesis   103                         103                              ST
  Verret et al (2012)[@b17-vhrm-12-387]             Any                     56                          58                               SM
  Siebenhofer et al (2012)[@b18-vhrm-12-387]        Any                     73                          68                               SM
  Thompson et al (2013)[@b23-vhrm-12-387]           Mechanical prosthesis   100                         100                              ST
  Dignan et al (2003)[@b19-vhrm-12-387]             Any                     157                         153                              SM

**Abbreviations:** AF, atrial fibrillation; OA, oral anticoagulation; SM, self-management; ST, self-testing.

###### 

Mean INR within target range

  Author (year)                                      Control group %   Intervention group %   Control vs intervention group *P*-value
  -------------------------------------------------- ----------------- ---------------------- -----------------------------------------
  Sawicki (1999)[@b6-vhrm-12-387]                    43.2              53                     0.22
  Cromheecke et al (2000)[@b8-vhrm-12-387]           49                55                     0.06
  Kortke et al (2001)[@b20-vhrm-12-387]              62                79                     **\<0.001**
  Sidhu et al (2001)[@b21-vhrm-12-387]               58                67.6                   **\<0.0001**
  Gadisseur et al (2003)[@b9-vhrm-12-387]            61.3              66.3                   0.14
  Sunderji et al (2004)[@b10-vhrm-12-387]            58.7              64.8                   0.23
  Menéndez-Jándulal et al (2005)[@b12-vhrm-12-387]   55.6              58.6                   **0.02**
  Voller et al (2005)[@b25-vhrm-12-387]              58.5              67.8                   **0.0061**
  Siebenhofer et al (2007)[@b15-vhrm-12-387]         57.1              72.4                   **\<0.001**

**Note:** Bold indicates statistical significance (*P*-value \<0.05).

**Abbreviation:** INR, international normalized ratio.

###### 

Mean time spent within INR target range

  Author (year)                                     Control group %   Intervention group %   Control vs intervention group *P*-value
  ------------------------------------------------- ----------------- ---------------------- -----------------------------------------
  Beyth et al (2000)[@b7-vhrm-12-387]               32                56                     **\<0.001**
  Sidhu et al (2001)[@b21-vhrm-12-387]              63.8              76.5                   **\<0.0001**
  Gadisseur et al (2003)[@b9-vhrm-12-387]           67.9              68.6                   0.33
  Khan et al (2004)[@b24-vhrm-12-387]               70.4              71.1                   NS
  Sunderji et al (2004)[@b10-vhrm-12-387]           63.2              71.8                   0.14
  Gardiner et al (2005)[@b11-vhrm-12-387]           66                61                     NS
  Menéndez-Jándula et al (2005)[@b12-vhrm-12-387]   64.9              64.3                   NS
  Fitzmaurice et al (2005)[@b13-vhrm-12-387]        68                70                     NS
  Christensen et al (2006)[@b14-vhrm-12-387]        68.9              78.7                   NS
  Siebenhofer et al (2007)[@b15-vhrm-12-387]        66.5              75.4                   **\<0.029**
  Matchar et al (2010)[@b16-vhrm-12-387]            62.4              66.2                   **\<0.001**
  Azarnoush et al (2011)[@b22-vhrm-12-387]          55.5              61.5                   **\<0.05**
  Verret et al (2012)[@b17-vhrm-12-387]             75.5              80                     0.79
  Thompson et al (2013)[@b23-vhrm-12-387]           45                52                     0.05

**Note:** Bold indicates statistical significance (*P*-value \<0.05).

**Abbreviations:** INR, international normalized ratio; NS, not significant.
